Jane Lebkowski has been actively involved in the development of cell and gene therapies since 1986 and is President of Regenerative Patch Technologies (RPT), a biotechnology firm developing composite stem cell-based implants targeting restoration of retinal architecture and function in patients with macular degeneration. In this role, Dr Lebkowski oversees all of RPT’s operations. From 2013-2017, Jane Lebkowski also served as Chief Scientific Officer and President of R&D at Asterias Biotherapeutics Inc, where she headed all preclinical, product, regulatory, and clinical development of Asterias’ regenerative medicine and dendritic cell based-cancer immunotherapy products. Prior to joining Asterias, Dr. Lebkowski was Senior Vice President of Regenerative Medicine and Chief Scientific Officer at Geron Corporation. Dr. Lebkowski led Geron’s human embryonic stem cell program from 1998-2012 and was responsible for all research, preclinical development, product development, manufacturing, and clinical development activities supporting cell-based therapies for several regenerative medicine indications including spinal cord injury and cardiovascular disease. From 1986-1998, Dr. Lebkowski was Vice President of Research and Development at Applied Immune Sciences where she directed activities to develop T cell based cancer immunotherapies for solid tumors, hematologic malignancies and AIDs. Following the acquisition of Applied Immune Sciences by Rhone Poulenc Rorer (RPR, currently Sanofi), Dr. Lebkowski remained at RPR as Vice President of Discovery Research. During Dr. Lebkowski’s tenure at RPR, she coordinated preclinical investigations of gene therapy approaches for treatment of cancer, cardiovascular disease and nervous system disorders, and directed vector formulations and delivery development. Dr. Lebkowski received her Ph.D. in Biochemistry from Princeton University in 1982, and completed a postdoctoral fellowship at the Department of Genetics, Stanford University in 1986. Dr. Lebkowski has published over 80 peer reviewed publication and has 13 issued U.S. patents. Dr. Lebkowski served on the board of Directors of the International Society of Stem Cell Research and is a former board member of the American Society for Gene and Cell Therapy. Dr Lebkowski has served on numerous scientific advisory boards and professional committees.
Dr. Farid Menaa is an inter- and multi-disciplinary professional with worldwide reputation. He has three international post-doctoral terms in Oncology, Dermatology, and Hematology; MBA Entrepreneurship and MD candidate. During his ongoing career, he has mainly contributed to the identification and functions of new human disease-causing genes and variants, formulated natural products for anti-aging and developed innovative theranostic strategies against cancers, cardiovascular diseases, diabetes, obesity and infectious diseases. He has more than 10 years’ experiences either in the academic, hospitals or industrial sectors. As Chief Scientific Officer and Vice-President R&D at Fluorotronics, Inc. he actively participated in the development of the disruptive “Carbon-Fluorine Spectroscopy”. Dr. Menaa collaborates with various organizations worldwide. He is a member of several prestigious medical and scientific organizations and editorial boards in the field of medicine, science, technology and business, including in the nano-segment. He has authored more than 100 articles including research and review articles, books, book chapters, textbooks, proceedings, and has participated to over 200 scientific international events including as co-organizer, keynote speaker, chairman. Dr. Menaa’s worldwide collaborations, holistic point of view and strong expertise in various fields led him to prevent, implement early diagnosis, and develop efficient and safer therapy.
Yuncang Li obtained his Ph.D. in Materials Science Engineering from Deakin University in 2004 and then took up a research position in Biomaterials Engineering at Deakin University until the end of 2014. He joined RMIT University in 2015. He was awarded an Australian Research Council (ARC) Future Fellowship and won a number of nationally competitive grants including ARC and Australian National Health and Medical Research Council projects. His research focuses on developing metallic biomaterials for medical applications. He has expertise in microstructure-mechanical property relationships, corrosion, and biocompatibility, surface modification, nanostructured metals and alloys, and metal foams. His research has led to 184 peer-reviewed original publications, with an H index of 31 and over 3180 citations (Google Scholar).
Kelvin GM Brockbank is Chief Executive Officer and Founder of Tissue Testing Technologies LLC, USA. He was a Research Professor of Bioengineering at Clemson University and Adjunct Professor of Regenerative Medicine and Cell Biology at the Medical University of South Carolina. His research interests include cell, tissue and organ cryopreservation for test systems and transplantation and manufacturing methods for cell-based bioengineered therapy products. His work has led to the establishment of two successful publicly traded low temperature technology platform companies, CryoLife, Inc. and Lifeline Scientific, Inc. He has over 500 publications and presentations at national and international conferences including more than 30 patents related to hypothermic, frozen and vitrified biomaterial preservation.
Dr. Nadia Benkirane is Research director and head of the “ Osteoarticular and Dental regenerative Nanomedicine” laboratory, at INSERM (French National Institute for Health and Medical Research), UMR 1109, Strasbourg, France. She was leader of “Active Biomaterials and Tissue Engineering” team INSERM 977. She received her Ph.D. from University Louis Pasteur, ULP, Strasbourg, France for the work on Development of pseudopeptides as synthetic vaccines. Dr. Jessel (Benkirane) then held a postdoctoral position in collaboration with the Institut Pasteur, Paris, France, working on Immunotherapy HIV, and another postdoctoral position on the application of modified peptides as vaccines against FMDV (Plum Island Animal Disease Center, ARS, USDA, Greenport, NY 11944-0848, USA). She joined the INSERM U595 in 2002 as a post-doc, and received the diploma to direct the research (HDR) in 2004. Dr. Jessel got the permanent position (CR1) in the INSERM 595 laboratory in 2004 and Research Director (DR2) position in the INSERM 977 and head of “active Biomaterials and Tissue Engineering team from 2009 until 2012). Currently Research Director (DR1) in the INSERM UMR 1109 (Osteoarticular and Dental Regenerative Nanomedicine" and heads the team. Dr. Jessel possesses expertise in diverse fields of molecular and cellular biology, immunochemistry, tissue engineering and biomedical engineering. In the last 10 years, she focused her research on the bio-functionalization of multilayered polyelectrolyte architectures with emphasis on the use of these architectures to induce specific cellular responses and gain control over cell proliferation and differentiation. Dr. Benkirane-Jessel have 138 publications (h index: 36) with peer-reviewed publications in high impact factor journals (Proc. Nat. Acad. Sci. USA; Adv. Mater.; Adv. Funct. Mater.; Small; Nanoletters, Biomaterials, ACS Nano), 5 chapters reviews and 5 international patents, she is a regular referee for a number of scientific journals (Nature nanotechnology, Nature Materials, ACS nano, Biomaterials, Nanoletters…). She is under the contract (Interface INSERM/Clinic 2008-2013) and she got also “Prime d’Excellence Scientifique” from the INSERM, 2010-2014 and the PEDR from the INSERM on 2016 for 4 years.
Dr. G.Subramanyam who is working as Professor of Cardiology and Director of Narayana Medical College Nellore (INDIA) was earlier Director vice chancellor of SVIMS University Tirupati (A.P) and chairman super specialty courses of Kathmandu University Nepal. He has more than 130 publications. He is a fellow of Directorate of tissue engineering IASR for outstanding scientific contribution2017. He has also received Ronald Ross research award 2017 in tissue engineering. He got best teacher award in 1998 from Government of A.P (India) He has more than 130 publications. His main area of interest is on stem cells, micronutrients and epidemiological studies
Professor.Dr.Ahmed G.Hegazi currently working as a professor of Microbiology and Immunology in National Research Center, Dokki, Giza, Egypt with a work experience of more than forty years. He bagged many awards and the recent one was “Merit Aware of Medical Sciences, 2016” and he has four patents, 224 Articles. He was Secretary General at African Federation of Apiculture Associations (AFAA) and member of many scientific boards and Editorial Board of many journals. His contributions to the field of Microbiology and Immunology was incredible and we are privileged to have him as Organizing member.
Dong-An Wang is a professor of Biomedical Engineering in City University of Hong Kong. His research interests include biomaterials, tissue engineering and gene delivery. He has done significant research work in his research areas and published over 100 high quality journal papers including Nature Materials, Advanced Functional Materials and Biomaterials etc. He has been often invited as a theme editor and reviewer for a number of top journals. He has been conferred with various research/academic awards.